Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14920940 | 0.81 | MAPT (0.48) | MAPTALDH1A1RAB9AGAAHTT | |
| SCHEMBL4581763 | 0.80 | TAS1R3 (0.38) | HTTSMN1; SMN2 | |
| SCHEMBL11224199 | 0.79 | GAA (0.42) | MAPTALDH1A1RAB9AGAAHTT | |
| SCHEMBL4582217 | 0.78 | GAA (0.48) | MAPTALDH1A1GAAHTTSMN1; SMN2 | |
| SCHEMBL3071601 | 0.76 | MEN1 (0.56) | MAPTALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL14934959 | 0.74 | SMN1; SMN2 (0.44) | MAPTALDH1A1RAB9AGAAHTT | |
| SCHEMBL19311948 | 0.74 | TSHR (0.49) | MAPTALDH1A1RAB9AGAAHTT | |
| SCHEMBL9566637 | 0.74 | SMN1; SMN2 (0.45) | MAPTALDH1A1GAAHTTSMN1; SMN2 | |
| SCHEMBL9817983 | 0.74 | ALOX5 (0.53) | MAPTALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL4580162 | 0.73 | ALDH1A1 (0.37) | MAPTALDH1A1RAB9AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351389-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2008-04-01 | — | — | US | disclosed |
| US-20050090689-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2005-04-28 | — | — | US | disclosed |
| US-6875864-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2005-04-05 | — | — | US | disclosed |
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO SUISSE SA (CH) | 2003-09-11 | — | — | US | disclosed |
| EP-0543482-B1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INT BV (NL) | 2002-02-06 | — | — | EP | disclosed |
| EP-0543482-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | ARGLU1, PRMT1, AADAC | MAPT 2319/4885ALDH1A1 741/4885RAB9A 272/4885 |
| US-20050090689-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | AADAC, ANXA3, AAAS | MAPT 1746/4885ALDH1A1 691/4885RAB9A 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.